In this page you can find the latest issue of the journal
The latest issue of Chemistry Today explores the renaissance and industrial evolution of peptide and oligonucleotide therapeutics. It covers process development, Industry 5.0 laboratories, the Critical Medicines Act, data maturity, investment strategies, siRNA discovery, novel manufacturing approaches, and features IOPC 2026 proceedings focused on peptide and oligonucleotide innovation.
“Contents from Magazine” offers curated articles and insights from the field of chemistry, focused on research, data, and scientific developments
15K articles and news from our archive.
What do you get when the Renaissance, Industrial Revolution, and Evolution converge? Exactly what peptide and oligonucleotide therapeutics are experiencing today. We have come a long way from hormone replacement therapy for…
We accelerate pharmaceutical innovation to enable earlier access to good medicines In modern pharmaceutical development, complex molecules, rising regulatory standards and pressure for robust IP protection demand more than traditional crystallization can…
For three decades, Europe has steadily shifted the production of widely used medicines—and their key ingredients—abroad, mainly to Asia. The result is a supply chain that depends heavily on India and China…
Regulatory information management (RIM) has been transformed over the past decade. Most organisations by now have modernised their global RIM systems, improved data quality and begun deploying AI and automation in targeted…
Linerixibat is an orally administered, minimally absorbed ileal bile acid transporter (IBAT) inhibitor developed to treat cholestatic pruritus associated with primary biliary cholangitis (PBC). Its mechanism is based on blocking…
Introduction Biotech companies backed by venture capital or private equity face very different pressures than traditional pharmaceutical organizations. Their timelines are compressed, their resources are constrained, and their survival depends on hitting…
Introduction: From Digitalisation to Intelligence Over the past decade, many laboratories across the chemical and pharmaceutical industries have undergone rapid digital transformation. Under the paradigm of Industry 4.0, laboratories have implemented automation,…
Context/Overview Breakthrough therapies often fail to reach patients. Not because biology doesn’t work, but because manufacturing cannot keep pace. Viral vectors, monoclonal antibodies, and gene therapies transform modern medicine. Yet the development…
Introduction Within the fields of chemistry and pharmaceuticals, claims are frequently formulated to safeguard a range of chemical substances instead of solely an individual identified molecule. Markush formulae, which consist of generic…
The manufacturing of antibody–oligonucleotide conjugates (AOCs) and oligo-peptide conjugates are transforming the precision, scalability, and therapeutic potential of targeted biologics. Advances in site-specific conjugation technologies—such as engineered cysteine residues, enzymatic tagging (e.g.,…
Synthetic Oligonucleotides and the oligonucleotide Space Synthetic oligonucleotides lie at the very core of progress in biotechnology and pharmaceutical R&D. Their properties and functionalities are unparalleled, spanning a broad spectrum of applications:…
INTERNATIONAL OLIGONUCLEOTIDES AND PEPTIDES CONFERENCE The IOPC is the leading event at the forefront of innovation, research, and novel developments June 9-11, 2026 Athens, Greece This section focuses on the International Oligonucleotides…
